表紙:症候群マルチプレックス診断市場:Covid-19の影響、戦略、および動向:症候群別(呼吸器系、敗血症、消化管など)、場所別、製品別、国別予測:市場分析、エグゼクティブガイドとカスタマイゼーション(2021~2025年)
市場調査レポート
商品コード
1028764

症候群マルチプレックス診断市場:Covid-19の影響、戦略、および動向:症候群別(呼吸器系、敗血症、消化管など)、場所別、製品別、国別予測:市場分析、エグゼクティブガイドとカスタマイゼーション(2021~2025年)

Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Place, by Product and by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 501 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
症候群マルチプレックス診断市場:Covid-19の影響、戦略、および動向:症候群別(呼吸器系、敗血症、消化管など)、場所別、製品別、国別予測:市場分析、エグゼクティブガイドとカスタマイゼーション(2021~2025年)
出版日: 2021年09月20日
発行: Howe Sound Research
ページ情報: 英文 501 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

COVIDパンデミックは、感染症診断の新たな世界の到来を告げるものです。感染症診断は変化しており、今後もさらに変化していくでしょう。

症候群検査は市場で実証されつつあます。市場参入者は二桁成長を報告しています。コストの削減、治療成績の向上、さらには抗微生物剤耐性との戦いにも貢献しています。

当レポートでは、症候群マルチプレックス診断市場について調査し、市場の概要とともに、症候群別、場所別、製品別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

  • 状況分析とCOVIDの影響の概要
  • エグゼクティブおよびマーケティングスタッフのためのガイド
  • 投資アナリストおよび経営コンサルタントのためのガイド
  • 大手企業の市場シェア-表とグラフ

第2章 イントロダクションと市場の定義

  • 症候群マルチプレックス検査とは何か
  • 症候群検査-診断における静かな革命
    • 症候群検査
  • 市場の定義
    • マルチプレックス市場規模
    • 通貨
  • 調査手法
    • 著者
    • ソース
  • 展望:ヘルスケア、IVD産業、およびCOVID-19パンデミック
    • 世界のヘルスケア支出
    • 診断への支出
    • 診断のための保険の重要な役割

第3章 感染症-病原体のガイド

  • コロナウイルス
    • 重症急性呼吸器症候群(SARS)
    • 中東呼吸器症候群(MERS)
    • COVID-19
  • HIV-ヒト免疫不全ウイルス(AIDS)
    • ウイルス学
    • 診断
    • 検査
  • HBV-B型肝炎
    • ウイルス学
    • メカニズム
    • 診断
    • 市場機会分析
  • HCV-C型肝炎
    • 分類法
    • 分子生物学
    • レプリケーション
    • 遺伝子型
    • 市場機会分析
  • 2.4HPV-ヒトパピローマウイルス
    • ウイルス学
    • 診断
    • 市場機会分析
  • インフルエンザ
    • ウイルス学
    • 検査
    • 市場機会分析
  • CTGC-クラミジア/淋病
    • 淋病
    • クラミジア
    • 検査
    • 市場機会分析
  • 結核
    • マイコバクテリア
    • 診断
    • 疫学
    • 分子診断検査
    • 市場機会分析
  • MRSA-メチシリン耐性黄色ブドウ球菌
    • 診断
    • FDA承認の分子検査
    • 市場機会分析
  • VRE-バンコマイシン耐性腸球菌
    • VREのためのFDA承認の分子診断検査
    • 市場機会分析

第4章 業界の概要

  • 業界の参加者
    • IVDサプライヤー
    • 独立検査室:専門/難解分野
    • 独立検査室:国/地域
    • 独立検査室:分析
    • 公立国立/地域研究所
    • 病院検査室
    • 開業医向け検査室
    • 監査機関
  • 臨床検査市場セグメント
    • 従来の市場セグメンテーション
    • ラボの焦点とセグメンテーション
    • 症候群検査市場のセグメント化
  • 業界構造
    • 病院検査シェア
    • 規模の経済
    • 開業医向け検査室
    • 医師とPOCT

第5章 市場動向

  • 成長促進要因
    • 診断のスピード
    • 症候群検査が費用に及ぼす影響
    • ポイントオブケアの利点
    • 症候群の検査、精度および診断リスク
    • 1回の訪問
    • アウトカムの改善
    • COVID-19パンデミックの影響
  • 成長抑制要因
    • 低価格
    • 管理/償還
    • 感染症の減少
    • 健康被害
    • 経済成長による生活水準の向上
    • パンデミック不況の影響
  • 計装と自動化
    • 市場シェアの鍵となる機器
    • 収縮機
    • 症候群検査は大型機器に移行するか
  • 診断技術の開発
    • Syndromictrends.com
    • 症候群と標的検査の比較
    • マルチプレックスパラダイムシフト
    • 敗血症検査市場-症候群の先導者
    • 1回の訪問と抗菌耐性
    • 症候群検査がPOCTの採用を促進
    • PCRの大きな未来

第6章 症候群検査 - 最近の進展

第7章 主要な症候群検査企業のプロファイル

第8章 世界の症候群マルチプレックス診断市場

  • 国別の世界の市場概要
    • 表-国別の世界の市場
    • チャート-国別の世界の市場
  • 世界市場-症候群別-概要
    • 表-世界市場-症候群別
    • チャート-世界市場-症候群別-基準/最終年の比較
    • チャート-世界市場-症候群別-基準年
    • チャート-世界市場-症候群別-年末
    • チャート-世界市場-症候群別-年別のシェア
    • チャート-世界市場-症候群別-セグメントの成長
  • 世界市場-場所別-概要
    • 表-世界市場-場所別
    • チャート-世界市場-場所別-基準/最終年の比較
    • チャート-世界市場-場所別-基準年
    • チャート-世界市場-場所別-年末
    • チャート-世界市場-場所別-年別のシェア
    • チャート-世界市場-場所別-セグメントの成長
  • 世界市場-製品別-概要
    • 表-世界市場-製品別
    • チャート-世界市場-製品別-基準/最終年度の比較
    • チャート-世界市場-製品別-基準年
    • チャート-世界市場-製品別-年末
    • チャート-世界市場-製品別-年別のシェア
    • チャート-世界市場-製品別-セグメントの成長

第9章 世界の症候群マルチプレックス市場-症候群別

  • 呼吸器
  • 消化管
  • 血液
  • 髄膜炎/脳炎
  • 性感染症
  • その他

第10章 世界の症候群マルチプレックス市場-場所別

  • 病院検査室
  • 外来検査室
  • POC
  • その他

第11章 世界の症候群マルチプレックス市場-製品別

  • 装置
  • カートリッジ
  • 試薬
  • その他

第12章 付録

図表

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Characteristics of Coronavirus Pandemic Infections
  • Table 3 COVID-19 Symptoms
  • Table 4 Classification of HIV Species
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 Influenza Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 Market Players by Type
  • Table 23 Clinical Laboratory Departments and Segments
  • Table 24 Laboratory Management Focus - Different Approaches
  • Table 25 Key Segmentation Variables Going Forward
  • Table 26 Possible Market Segments of Syndromic Multiplex Market
  • Table 27 Five Factors Driving Growth
  • Table 28 How SMT Improves Outcomes
  • Table 29 Four Factors Limiting Growth
  • Table 30 - Global Market by Region
  • Table 31 Global Market by Syndrome
  • Table 32 Global Market by Place
  • Table 33 Global Market by Product
  • Table 34 Respiratory by Country
  • Table 35 Gastrointestinal by Country
  • Table 36 Blood by Country
  • Table 37 Meningitis/Encephalitis by Country
  • Table 38 Sexually Transmitted Disease by Country
  • Table 39 Other by Country
  • Table 40 Hospital Lab by Country
  • Table 41 Outpatient Lab by Country
  • Table 42 Point of Care by Country
  • Table 43 Other by Country
  • Table 44 Instruments by Country
  • Table 45 Cartridges by Country
  • Table 46 Reagents by Country
  • Table 47 Other Product by Country
  • Table 48 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 The Global Healthcare Spending Picture
  • Figure 3 The Lab Test Pie
  • FIGURE 4 STRUCTURE OF CORONAVIRUSES
  • Figure 5 HIV Virion
  • Figure 6 Diagram of the HIV Replication Cycle
  • Figure 7 The Structure of the HBV Virus
  • Figure 8 Hepatitis B Replication
  • Figure 9 Structure of the HCV Virus
  • Figure 10 HCV Replication Cycle
  • Figure 11 Structure of the Influenza Virion
  • Figure 12 Influenza Replication
  • Figure 13 Scanning Electronmicrograph of Tuberculosis
  • Figure 14 Chart Death Rates and Infectious Disease Decline
  • Figure 15 Comparing Syndromic and Targeted Testing
  • Figure 16 The Multiplex Paradigm Shift
  • Figure 17 Global Market Share Chart
  • Figure 18 Global Market by Syndrome - Base vs. Final
  • Figure 19 Global Market by Syndrome Base Year
  • Figure 20 Global Market by Syndrome End Year
  • Figure 21 Syndrome Share by Year
  • Figure 22 Syndrome Segments Growth
  • Figure 23 Global Market by Place - Base vs. Final
  • Figure 24 Global Market by Place Base Year
  • Figure 25 Global Market by Place End Year
  • Figure 26 Place Share by Year
  • Figure 27 Place Segments Growth
  • Figure 28 Global Market by Product - Base vs. Final
  • Figure 29 Global Market by Product Base Year
  • Figure 30 Global Market by Product End Year
  • Figure 31 Product Share by Year
  • Figure 32 Product Segments Growth
  • Figure 33 Respiratory Growth
  • Figure 34 Gastrointestinal Diagnostics Growth
  • Figure 35 Blood Growth
  • Figure 36 Meningitis/Encephalitis Growth
  • Figure 37 Sexually Transmitted Disease Growth
  • Figure 38 Other Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 Point of Care Growth
  • Figure 42 Other Growth
  • Figure 43 Instruments Growth
  • Figure 44 Cartridges Growth
  • Figure 45 Reagents Growth
  • Figure 46 Other Product Growth
目次

OVERVIEW:

The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2025. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis & COVID Impact Overview
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 What are Syndromic Multiplex Tests?
  • 2.2 Syndromic Testing - the quiet revolution in diagnostics
    • 2.2.1 Syndromic Testing - more than Panels
  • 2.3 Market Definition
    • 2.3.1 Multiplex Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 The Coronavirus
    • 3.1.1 Severe acute respiratory syndrome (SARS)
    • 3.1.2 Middle East respiratory syndrome (MERS)
    • 3.1.3 COVID-19. The SARS CoV 2 Virus
      • 3.1.3.1 Signs and symptoms
      • 3.1.3.2 Transmission
      • 3.1.3.3 Diagnosis
      • 3.1.3.4 Prevention
      • 3.1.3.5 Management
      • 3.1.3.6 Prognosis
      • 3.1.3.7 New Strains and Subsequent Mutations
  • 3.3 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.3.1 Virology
      • 3.3.1.1 Classification
      • 3.3.1.2 Structure and genome
      • 3.3.1.3 Tropism
      • 3.3.1.4 Replication cycle
      • 3.3.1.5 Genetic variability
    • 3.3.2 Diagnosis
    • 3.3.3 Testing
      • 3.3.3.1 Antibody tests
      • 3.3.3.2 Point of Care Tests (POCT)
      • 3.3.3.3 Antigen Tests
      • 3.3.3.4 Nucleic acid-based tests (NAT)
      • 3.3.3.5 Other tests used in HIV treatment
  • 3.4 HBV - Hepatitis B
    • 3.4.1 Virology
      • 3.4.1.1 Genome
      • 3.4.1.2 Pathogenesis
      • 3.4.1.3 Hepatitis B virus replication
      • 3.4.1.4 Serotypes and genotypes
    • 3.4.2 Mechanisms
    • 3.4.3 Diagnosis
    • 3.4.4 Market Opportunity Analysis
  • 3.5 HCV - Hepatitis C
    • 3.5.1 Taxonomy
      • 3.5.1.1 Structure
      • 3.5.1.2 Genome
    • 3.5.2 Molecular biology
    • 3.5.3 Replication
    • 3.5.4 Genotypes
      • 3.5.4.1 Clinical importance
    • 3.5.5 Market Opportunity Analysis
  • 3.6 2.4 HPV - Human papillomavirus
    • 3.6.1 Virology
      • 3.6.1.1 E6/E7 proteins
      • 3.6.1.2 Role in cancer
      • 3.6.1.3 E2 research
      • 3.6.1.4 Latency period
      • 3.6.1.5 Clearance
    • 3.6.2 Diagnosis
      • 3.6.2.1 Cervical testing
      • 3.6.2.2 Oral testing
      • 3.6.2.3 Testing men
      • 3.6.2.4 Other testing
    • 3.6.3 Market Opportunity Analysis
  • 3.7 Influenza
    • 3.7.1 Virology
      • 3.7.1.1 Types of virus
      • 3.7.1.2 Influenzavirus A
      • 3.7.1.3 Influenzavirus B
      • 3.7.1.4 Influenzavirus C
      • 3.7.1.5 Structure, properties, and subtype nomenclature
      • 3.7.1.6 Replication
    • 3.7.2 Testing
      • 3.7.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.7.3 Market Opportunity Analysis
  • 3.8 CTGC - Chlamydia/Gonorhea
    • 3.8.1 Gonorrhea
      • 3.8.1.1 Diagnosis
      • 3.8.1.2 Screening
    • 3.8.2 Chlamydia
      • 3.8.2.1 Diagnosis
      • 3.8.2.2 Screening
    • 3.8.3 Testing
      • 3.8.3.1 Nucleic acid amplification tests (NAATs)
      • 3.8.3.2 Performance of NAAT Tests
    • 3.8.4 Market Opportunity Analysis
  • 3.9 Tuberculosis
    • 3.9.1 Mycobacteria
    • 3.9.2 Diagnosis
      • 3.9.2.1 Active tuberculosis
      • 3.9.2.2 Latent tuberculosis
    • 3.9.3 Epidemiology
    • 3.9.4 Molecular Diagnostic Tests
    • 3.9.5 Market Opportunity Analysis
  • 3.10 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.10.1 Diagnosis
    • 3.10.2 FDA Approved Molecular Tests
    • 3.10.3 Market Opportunity Analysis
  • 3.11 VRE - Vancomycin-resistant Enterococcus
    • 3.11.1 FDA Approved MDx Tests for VRE
    • 3.11.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Industry Participants
    • 4.1.1 IVD Supplier
    • 4.1.2 Independent lab specialized/esoteric
    • 4.1.3 Independent lab national/regional
    • 4.1.4 Independent lab analytical
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician lab
    • 4.1.8 Audit body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Speed of Diagnosis
    • 5.1.2 Effect of Syndromic Testing on Costs
    • 5.1.3 Point of Care Advantage
    • 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 5.1.5 Single Visits
    • 5.1.6 Improvement in Outcomes
    • 5.1.7 Impact of the COVID-19 Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Prices
    • 5.2.2 Administration/reimbursement
    • 5.2.3 Infectious Disease is Declining But...
    • 5.2.4 Wellness Hurts
    • 5.2.5 Economic Growth improves Living Standards
    • 5.2.6 Impact of the Pandemic Recession
  • 5.3 Instrumentation and Automation
    • 5.3.1 Instruments Key to Market Share
    • 5.3.2 The Shrinking Machine
    • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4 Diagnostic Technology Development
    • 5.4.1 Syndromictrends.com
    • 5.4.2 Comparing Syndrome and Targeted Testing
    • 5.4.3 The Multiplex Paradigm Shift
    • 5.4.4 The Sepsis Testing Market - Bellwether for Syndromics
    • 5.4.5 The Single Visit and AntiMicrobial Resistance
    • 5.4.6 Syndromics drives POCT adoption
    • 5.4.7 A Big Future for PCR?

6 Syndromic Testing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 QuantuMDx Developing Syndromic Panels for European Launch
  • 6.3 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
  • 6.4 QuantumDx Gets CE Mark for Rapid PoC PCR System
  • 6.5 Bio-Rad Laboratories, Seegene Partner for MDx Development
  • 6.6 Baebies to Expand Finder Platform
  • 6.7 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
  • 6.8 Binx Health Targeting Clinics, DTC & OTC With STI Tests
  • 6.9 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
  • 6.10 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
  • 6.11 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
  • 6.12 New Approach Involves Silicon-Based Test for Infectious Disease Screening
  • 6.13 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • 6.14 Qiagen sees NeuMoDx as Growth Vehicle
  • 6.15 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • 6.16 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • 6.17 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • 6.18 Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • 6.19 ChromaCode Raises Additional $10M
  • 6.20 COVID-19 Patients Need Syndromic Testing
  • 6.21 GenMark Diagnostics - New Respiratory Panel due in June
  • 6.22 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • 6.23 Exact Diagnostics launches respiratory panel control
  • 6.24 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • 6.25 Nanomix Receives CE Mark for Diagnostic
  • 6.26 Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • 6.27 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • 6.28 QIAGEN's New GI Panel Performance Assessed
  • 6.29 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • 6.30 Applied BioCode Obtains FDA Clearance
  • 6.31 Meridian Bioscience to Acquire GenePOC Inc
  • 6.32 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • 6.33 Qiagen gets FDA clearance for syndromic testing system
  • 6.34 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • 6.35 Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • 6.36 Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • 6.37 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • 6.38 QuantuMDx and Molbio announce MoU
  • 6.39 Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • 6.40 Mobidiag Inks European, Middle Eastern Distribution Deals
  • 6.41 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial

7 Profiles of Key Syndromic Testing Companies

  • 7.1 Abacus Diagnostica
  • 7.2 Abbott Diagnostics
  • 7.3 Accelerate Diagnostics
  • 7.4 Ador Diagnostics
  • 7.5 Akonni Biosystems
  • 7.6 Alveo Technologies
  • 7.7 Antelope Dx
  • 7.8 Applied BioCode
  • 7.9 Aus Diagnostics
  • 7.10 Baebies
  • 7.11 Beckman Coulter Diagnostics
  • 7.12 Becton, Dickinson and Company
  • 7.13 Binx Health
  • 7.14 Biocartis
  • 7.15 BioFire Diagnostics (bioMérieux)
  • 7.16 bioMérieux Diagnostics
  • 7.17 Bio-Rad Laboratories, Inc
  • 7.18 Bosch Healthcare Solutions GmbH
  • 7.19 Cepheid (Danaher)
  • 7.20 Credo Diagnostics Biomedical
  • 7.21 Cue Health
  • 7.22 Curetis N.V. / Curetis GmbH
  • 7.23 Diagenode Diagnostics
  • 7.24 Diasorin S.p.A
  • 7.25 Enzo Life Sciences, Inc
  • 7.26 Eurofins Scientific
  • 7.27 Fluxergy
  • 7.28 Fusion Genomics
  • 7.29 Genetic Signatures
  • 7.30 GenMark Dx (Roche)
  • 7.31 Hibergene Diagnostics
  • 7.32 Hologic
  • 7.33 Immunexpress
  • 7.34 Inflammatix
  • 7.35 Invetech
  • 7.36 Janssen Diagnostics
  • 7.37 Karius
  • 7.38 Lexagene
  • 7.39 LightDeck Diagnostics
  • 7.40 Lucira Health
  • 7.41 Luminex Corp
  • 7.42 Maxim Biomedical
  • 7.43 Meridian Bioscience
  • 7.44 Mesa Biotech (Thermo Fisher)
  • 7.45 Millipore Sigma
  • 7.46 Mobidiag (Hologic)
  • 7.47 Molbio Diagnostics
  • 7.48 Nanomix
  • 7.49 Novel Microdevices
  • 7.50 Operon
  • 7.51 Oxford Nanopore Technologies
  • 7.52 Panagene
  • 7.53 Perkin Elmer
  • 7.54 Primerdesign (Novacyt)
  • 7.55 Prominex
  • 7.56 Qiagen Gmbh
  • 7.57 Quantumdx
  • 7.58 Quidel
  • 7.59 Roche Molecular Diagnostics
  • 7.60 Saw Diagnostics
  • 7.61 Seegene
  • 7.62 Siemens Healthineers
  • 7.63 Sona Nanotech
  • 7.64 SpeeDx
  • 7.65 T2 Biosystems
  • 7.66 Talis Biomedical
  • 7.67 Thermo Fisher Scientific Inc
  • 7.68 Veramarx
  • 7.69 Visby Medical
  • 7.70 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Place - Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth
  • 8.4 Global Market by Product - Overview
    • 8.4.1 Table - Global Market by Product
    • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Product - Base Year
    • 8.4.4 Chart - Global Market by Product - End Year
    • 8.4.5 Chart - Global Market by Product - Share by Year
    • 8.4.6 Chart - Global Market by Product - Segments Growth

9 Global Syndromic Multiplex Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other Syndrome
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Infectious Disease Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other - by Country
    • 10.4.2 Chart - Other Place Growth

11 Global MDx Infectious Disease Markets - by Product

  • 11.1 Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 Cartridges
    • 11.2.1 Table Cartridges - by Country
    • 11.2.2 Chart - Cartridges Growth
  • 11.3 Reagents
    • 11.3.1 Table Reagents - by Country
    • 11.3.2 Chart - Reagents Growth
  • 11.4 Other Product
    • 11.4.1 Table Other Product - by Country
    • 11.4.2 Chart - Other Product Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule